Bio Green Med Solution (BGMS)


Market Price (11/19/2026): $0.6 | Market Cap: $4.0 MilSector: Industrials | Industry: Building Products

Bio Green Med Solution (BGMS)


Market Price (11/19/2026): $0.6
Market Cap: $4.0 Mil
Sector: Industrials
Industry: Building Products

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -91%

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 2658%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -38%

Megatrend and thematic drivers
Megatrends include Health & Wellness Trends, and Biotechnology & Genomics. Themes include Nutritional Supplements, Organic & Natural Products, Show more.

Weak multi-year price returns
2Y Excs Rtn is -113%, 3Y Excs Rtn is -157%

Penny stock
Mkt Price is 0.6

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -3.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -141%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 29%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -43%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -43%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -49%

High stock price volatility
Vol 12M is 113%

Key risks
BGMS key risks include [1] a material going-concern risk due to its dire financial instability, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -91%
1 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 2658%
2 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -38%
3 Megatrend and thematic drivers
Megatrends include Health & Wellness Trends, and Biotechnology & Genomics. Themes include Nutritional Supplements, Organic & Natural Products, Show more.
4 Weak multi-year price returns
2Y Excs Rtn is -113%, 3Y Excs Rtn is -157%
5 Penny stock
Mkt Price is 0.6
6 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -3.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -141%
7 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 29%
8 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -43%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -43%
9 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -49%
10 High stock price volatility
Vol 12M is 113%
11 Key risks
BGMS key risks include [1] a material going-concern risk due to its dire financial instability, Show more.

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/18/2026

Nov 17: down 9.3% in one day (S&P 500 down 1.0%)
The stock declined without company news. The S&P 500 also fell, as slower retail sales dragged on the market.

Down 47.7% since its Jul 1 high (S&P 500 down 1.8%)
The stock declined significantly without company news during this period, while the S&P 500 rose. Key drops occurred on July 6 and September 17, both without company headlines, and on November 11.

Nov 13: down 9.8% the day after its Nov 12 earnings report (S&P 500 down 0.4%)
The stock declined after Bio Green Med Solution reported third quarter financial results. The latest reported figures available were 2026Q2 revenue of $0M, net income of $-0M, and diluted EPS of $-0.08.

Show more
Prices as of 11/18/2026

Nov 17: down 9.3% in one day (S&P 500 down 1.0%)
The stock declined without company news. The S&P 500 also fell, as slower retail sales dragged on the market.

Down 47.7% since its Jul 1 high (S&P 500 down 1.8%)
The stock declined significantly without company news during this period, while the S&P 500 rose. Key drops occurred on July 6 and September 17, both without company headlines, and on November 11.

Nov 13: down 9.8% the day after its Nov 12 earnings report (S&P 500 down 0.4%)
The stock declined after Bio Green Med Solution reported third quarter financial results. The latest reported figures available were 2026Q2 revenue of $0M, net income of $-0M, and diluted EPS of $-0.08.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -35.4% change in BGMS stock from 7/31/2026 to 11/18/2026 was primarily driven by a -46.5% change in the company's P/S Multiple.
(LTM values as of)731202611182026Change
Stock Price ($)0.890.57-35.4%
Change Contribution By: 
Total Revenues ($ Mil)2246.5%
P/S Multiple3.21.7-46.5%
Shares Outstanding (Mil)57-17.6%
Cumulative Contribution-35.4%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/18/2026
ReturnCorrelation
BGMS-35.4% 
Market (SPY)-2.0%1.4%
Sector (XLI)-8.2%-2.2%

Fundamental Drivers

The -41.0% change in BGMS stock from 4/30/2026 to 11/18/2026 was primarily driven by a -75.8% change in the company's P/S Multiple.
(LTM values as of)430202611182026Change
Stock Price ($)0.970.57-41.0%
Change Contribution By: 
Total Revenues ($ Mil)12199.1%
P/S Multiple7.01.7-75.8%
Shares Outstanding (Mil)57-18.5%
Cumulative Contribution-41.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/18/2026
ReturnCorrelation
BGMS-41.0% 
Market (SPY)2.1%-3.8%
Sector (XLI)-5.2%-3.9%

Fundamental Drivers

The -67.7% change in BGMS stock from 10/31/2025 to 11/18/2026 was primarily driven by a -99.3% change in the company's P/S Multiple.
(LTM values as of)1031202511182026Change
Stock Price ($)1.780.57-67.7%
Change Contribution By: 
Total Revenues ($ Mil)0222240.0%
P/S Multiple242.21.7-99.3%
Shares Outstanding (Mil)17-79.5%
Cumulative Contribution-67.7%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/18/2026
ReturnCorrelation
BGMS-67.7% 
Market (SPY)8.2%10.5%
Sector (XLI)7.4%5.4%

Fundamental Drivers

null
null

Market Drivers

10/31/2023 to 11/18/2026
ReturnCorrelation
BGMS  
Market (SPY)81.1%10.1%
Sector (XLI)74.6%5.8%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
BGMS Return-----72%-61%-89%
Peers Return55%-6%49%16%30%8%254%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
BGMS Win Rate----0%36% 
Peers Win Rate63%50%60%53%53%47% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
BGMS Max Drawdown------64% 
Peers Max Drawdown-18%-41%-29%-24%-26%-29% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: WTS, WMS, GFF, UFPI, PPIH.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/18/2026 (YTD)

How Low Can It Go

BGMS has limited trading history. Below is the Industrials sector ETF (XLI) in its place.

EventXLIS&P 500
2025 US Tariff Shock
  % Loss-15.8%-18.8%
  % Gain to Breakeven18.8%23.1%
  Time to Breakeven34 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-11.7%-9.5%
  % Gain to Breakeven13.2%10.5%
  Time to Breakeven45 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-20.1%-24.5%
  % Gain to Breakeven25.1%32.4%
  Time to Breakeven125 days427 days
2020 COVID-19 Crash
  % Loss-41.6%-33.7%
  % Gain to Breakeven71.2%50.9%
  Time to Breakeven231 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-23.7%-19.2%
  % Gain to Breakeven31.1%23.8%
  Time to Breakeven120 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-11.1%-12.2%
  % Gain to Breakeven12.5%13.9%
  Time to Breakeven51 days62 days

Compare to WTS, WMS, GFF, UFPI, PPIH

In The Past

State Street Industrial Select Sector SPDR ETF's stock fell -15.8% during the 2025 US Tariff Shock. Such a loss loss requires a 18.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

BGMS has limited trading history. Below is the Industrials sector ETF (XLI) in its place.

EventXLIS&P 500
2022 Inflation Shock & Fed Tightening
  % Loss-20.1%-24.5%
  % Gain to Breakeven25.1%32.4%
  Time to Breakeven125 days427 days
2020 COVID-19 Crash
  % Loss-41.6%-33.7%
  % Gain to Breakeven71.2%50.9%
  Time to Breakeven231 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-23.7%-19.2%
  % Gain to Breakeven31.1%23.8%
  Time to Breakeven120 days105 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-22.5%-17.9%
  % Gain to Breakeven29.0%21.8%
  Time to Breakeven114 days123 days
2008-2009 Global Financial Crisis
  % Loss-60.5%-53.4%
  % Gain to Breakeven153.2%114.4%
  Time to Breakeven700 days1085 days

Compare to WTS, WMS, GFF, UFPI, PPIH

In The Past

State Street Industrial Select Sector SPDR ETF's stock fell -15.8% during the 2025 US Tariff Shock. Such a loss loss requires a 18.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Bio Green Med Solution (BGMS)

Bio Green Med Solution (BGMS), operating as Cyclacel Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of cancer and other proliferative diseases. The company is dedicated to addressing significant unmet medical needs by advancing a pipeline of drug candidates designed to target the underlying mechanisms of these complex conditions. Through its research and development efforts, BGMS aims to improve patient outcomes in challenging disease areas.

The company's core business revolves around its proprietary development programs, each featuring a distinct therapeutic candidate in clinical trials. Key programs include fadraciclib, a cyclin dependent kinase (CDK) inhibitor in Phase 1/2 for solid tumors and chronic lymphocytic leukemia; CYC140, a polo-like kinase inhibitor also in Phase 1/2 for advanced leukemias and solid tumors; and Sapacitabine, a novel nucleoside analog undergoing Phase 1/2 trials for acute myeloid leukemia and myelodysplastic syndrome. Additionally, BGMS is developing seliciclib, another CDK inhibitor, which is being evaluated in investigator-sponsored trials for Cushing's disease and advanced rheumatoid arthritis, demonstrating a diversified approach to drug development.

Bio Green Med Solution primarily serves patients suffering from a range of severe conditions, including various hematological malignancies such as chronic lymphocytic leukemia, acute myeloid leukemia, and myelodysplastic syndromes, as well as those with solid tumors. Beyond oncology, the company's therapies target patients with Cushing's disease and advanced rheumatoid arthritis. BGMS strategically partners with leading institutions, such as the University of Texas MD Anderson Cancer Center, to conduct clinical evaluations, reinforcing its commitment to bringing innovative and effective treatment options to patients globally.

AI Analysis | Feedback

A small, early-stage Merck, but purely focused on developing new cancer drugs that are still in clinical trials.

Like a startup biotech aiming to discover the next breakthrough cancer treatment, similar to an early-stage Gilead Sciences.

Moderna, but for oncology drugs that are currently in clinical development, rather than vaccines.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer

Datuk Dr. Doris Wong Sing Ee was elected as the Chief Executive Officer and Executive Director of Bio Green Med Solution (formerly Cyclacel Pharmaceuticals, Inc.) in February 2025 after acquiring a controlling 70% stake in the company. She brings over 20 years of experience in various industries. Since October 2020, she has served as an Executive Director of Metronic Global Bhd, an investment holding company, where she has been responsible for optimizing financial operations, establishing business goals, advising the board of directors on organizational activities, and executing special business projects. Dr. Wong has also been involved in various investment opportunities focused on business diversification, revenue generation, and increasing shareholders' wealth. Prior to her appointment at Cyclacel, she served as an independent director and a member of the audit and compensation committees of Energem Corp from November 2021 until January 2023.

Kiu Cu Seng, Chief Financial Officer

Kiu Cu Seng was appointed as Executive Director, Secretary, and Chief Financial Officer of Bio Green Med Solution (formerly Cyclacel Pharmaceuticals, Inc.) in February 2025. He brings significant accounting and audit experience to the company.

AI Analysis | Feedback

The public company Bio Green Med Solution (symbol: BGMS) faces several key risks, primarily stemming from its nature as a clinical-stage biopharmaceutical company, as described in the provided background information. Here are the key risks:
  1. Clinical Trial and Regulatory Approval Risk: The most significant risk for Bio Green Med Solution, based on the description, is the inherent uncertainty and high failure rate associated with clinical trials and the subsequent regulatory approval process for new drug candidates. The company's development programs, including fadraciclib, CYC140, Sapacitabine, and seliciclib, are all in Phase 1/2 clinical trials or investigator-sponsored trials. There is no guarantee that these drug candidates will demonstrate sufficient efficacy or safety in later-stage trials, or that they will ultimately receive the necessary regulatory approvals from health authorities like the FDA to be commercialized. Failure at any stage of development or inability to obtain approval would severely impact the company's prospects.
  2. Product Pipeline and Development Stage Risk: As a clinical-stage biopharmaceutical company, Bio Green Med Solution, as described, does not currently have any approved commercial products. Its future success and ability to generate revenue are entirely dependent on the successful development, approval, and commercialization of its pipeline candidates. If none of these candidates reach the market, the company would lack a sustainable revenue stream.
  3. Funding and Capital Needs: The research and development of pharmaceutical products, especially through extensive clinical trials, are highly capital-intensive processes. Bio Green Med Solution, as described, requires substantial ongoing funding to advance its various drug development programs. There is a risk that the company may not be able to secure adequate additional financing on favorable terms, or at all, which could lead to delays, curtailment, or even discontinuation of critical research and development efforts.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Capital Allocation Decisions (Bio Green Med Solution, Inc. - BGMS)

Share Issuance

  • Bio Green Med Solution, Inc. implemented a 1-for-15 reverse stock split on its common stock, effective July 7, 2025, to meet Nasdaq bid price requirements. This action reduced the number of outstanding common shares from 23,759,475 to 1,583,965.
  • The company executed other reverse stock splits, including a 1-for-15 split on December 18, 2023, and a 1-for-16 split on May 12, 2025.
  • Bio Green Med Solution entered into multiple Warrant Exchange Agreements where existing warrants to purchase common stock were exchanged for newly issued common shares.

Inbound Investments

  • Around late 2024/early 2025, there was an investment of $3.1 million in Preferred Stock, concurrently with the appointment of an Interim CEO.

Outbound Investments

  • In September 2025, Bio Green Med Solution, Inc. completed the acquisition of Fitters Sdn. Bhd., a Malaysia-based company specializing in fire safety and protection solutions, diversifying its business portfolio. As part of this Exchange Transaction, BGMS issued 699,158 shares of its common stock, representing 19.99% of its then-issued and outstanding common stock, in exchange for all of Fitters' equity interests.
  • On October 6, 2025, the company acquired Assets and Rights of Plogosertib from Tethra Biosciences Inc. for $0.47 million.

Capital Expenditures

  • Bio Green Med Solution Inc reported $0 in capital expenditures for Q3 2024.
  • The company also reported $0 in capital expenditures for several quarters, including June 30, 2025, March 31, 2025, December 31, 2024, and September 30, 2024.

Better Bets vs. Bio Green Med Solution (BGMS)

Peer Outperformance in Building Products

null
Share of Building Products constituents that BGMS has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
8%
of 37 industry peers · -57.1% return
3Y
—
insufficient peer history
5Y
—
insufficient peer history
null
Median price return by industry across the Industrials sector, ranked by 5Y. Building Products is BGMS's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Construction & Engineering 28 -11.3%82.8%103.5% FIX 1032% · STRL 856% · AGX 671%
Construction Machinery & Heavy Transportation Equipment 14 12.9%60.3%103.2% ALSN 271% · WAB 216% · CAT 201%
Marine Transportation 5 18.5%24.6%96.8% MATX 143% · KEX 125%
Aerospace & Defense 57 3.5%45.4%45.4% ATI 1006% · FTAI 838% · HWM 616%
Trading Companies & Distributors 19 18.2%31.5%38.1% DXPE 361% · URI 200% · AIT 185%
Industrial Machinery & Supplies & Components 71 5.3%42.0%31.2% CRS 812% · MLI 279% · SYM 238%
Rail Transportation 7 36.5%62.8%30.3% CSX 52% · UNP 40% · NSC 30%
Diversified Support Services 35 17.1%30.1%25.8% CXW 183% · OPLN 128% · CACI 123%
Building Products ← 34 1.6%1.6%15.5% MOD 1155% · GFF 408% · TT 125%
Cargo Ground Transportation 16 41.7%12.6%8.6% XPO 303% · R 281% · ARCB 27%
Office Services & Supplies 10 25.2%15.4%6.4% PBI 147% · HNI 40% · MSA 23%
Industrial Conglomerates 17 17.2%4.5%-5.0% CSW 104% · CSL 74% · DD 73%
Electrical Components & Equipment 40 -13.4%50.3%-9.4% POWL 1707% · VRT 635% · BE 473%
Data Processing & Outsourced Services 6 -8.9%-4.9%-11.0% EXLS 56% · BR 17% · G -11%
Research & Consulting Services 13 1.7%-19.2%-23.4% HURN 242% · FCN 36% · BAH 7%
Passenger Airlines 11 4.3%59.6%-30.2% LTM 3486% · UAL 127% · DAL 120%
Agricultural & Farm Machinery 17 14.8%-18.1%-32.8% DE 93% · TTC 7% · AGCO 3%
Environmental & Facilities Services 29 -19.3%15.1%-35.5% GEO 257% · CLH 164% · RSG 93%
Security & Alarm Services 9 -46.4%23.7%-39.4% BCO 85%
Human Resource & Employment Services 22 20.9%-19.8%-40.5% ADP 44% · FA 25% · PAYX 6%
Air Freight & Logistics 12 -31.8%-10.7%-44.0% FDX 79% · CHRW 65% · EXPD 57%
Passenger Ground Transportation 3 -18.9%26.3%-53.9% UBER 53% · CAR -54% · LYFT -64%
Airport Services 4 -43.9%-66.6%-83.5% JOBY -49%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Title
0ARTICLES

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

BGMSWTSWMSGFFUFPIPPIHMedian
NameBio Gree.Watts Wa.Advanced.Griffon UFP Indu.Perma-Pi. 
Mkt Price0.60363.71119.29107.2879.5527.7593.41
Mkt Cap0.012.29.04.74.2-4.7
Rev LTM22,7943,2612,0436,407-2,794
Op Inc LTM-3599675435290-435
FCF LTM-1370530267195-267
FCF 3Y Avg-6337485303332-332
CFO LTM-1434767305381-381
CFO 3Y Avg-6384706346557-384

Growth & Margins

BGMSWTSWMSGFFUFPIPPIHMedian
NameBio Gree.Watts Wa.Advanced.Griffon UFP Indu.Perma-Pi. 
Rev Chg LTM2,658.0%18.7%9.2%3.0%-0.7%-9.2%
Rev Chg 3Y Avg862.2%11.7%4.9%-7.0%-5.5%-4.9%
Rev Chg Q460.5%19.0%4.6%3.2%11.1%-11.1%
QoQ Delta Rev Chg LTM20.0%4.3%1.2%0.8%2.8%-2.8%
Op Inc Chg LTM61.8%34.0%0.4%1.9%-26.6%-1.9%
Op Inc Chg 3Y Avg51.6%20.3%-0.4%14.1%-25.5%-14.1%
Op Mgn LTM-141.5%21.4%20.7%21.3%4.5%-20.7%
Op Mgn 3Y Avg-10,451.9%19.2%22.5%22.2%6.2%-19.2%
QoQ Delta Op Mgn LTM53.5%2.0%-0.7%0.2%-0.5%-0.2%
CFO/Rev LTM-42.5%15.5%23.5%14.9%5.9%-14.9%
CFO/Rev 3Y Avg-7,271.1%15.5%23.1%17.7%8.5%-15.5%
FCF/Rev LTM-42.6%13.3%16.3%13.1%3.0%-13.1%
FCF/Rev 3Y Avg-7,271.1%13.7%15.9%15.5%5.1%-13.7%

Valuation

BGMSWTSWMSGFFUFPIPPIHMedian
NameBio Gree.Watts Wa.Advanced.Griffon UFP Indu.Perma-Pi. 
Mkt Cap0.012.29.04.74.2-4.7
P/S1.84.42.82.30.7-2.3
P/Op Inc-1.220.413.310.714.5-13.3
P/EBIT-1.220.313.410.912.8-12.8
P/E-2.427.322.214.518.1-18.1
P/CFO-4.128.111.715.311.0-11.7
Total Yield-44.0%4.3%5.2%7.7%7.4%-5.2%
Dividend Yield0.0%0.6%0.7%0.9%1.9%-0.7%
FCF Yield 3Y Avg-3.7%4.6%8.6%5.6%-5.1%
D/E0.00.00.20.20.1-0.1
Net D/E-0.9-0.00.20.2-0.1--0.0

Returns

BGMSWTSWMSGFFUFPIPPIHMedian
NameBio Gree.Watts Wa.Advanced.Griffon UFP Indu.Perma-Pi. 
1M Rtn-35.7%1.9%-6.6%15.8%1.7%-1.4%0.1%
3M Rtn-33.7%-2.8%-18.4%4.5%-11.6%4.7%-7.2%
6M Rtn-37.8%22.0%-12.6%29.3%0.3%-11.7%-5.7%
12M Rtn-55.2%37.3%-15.6%62.1%-8.9%18.5%4.8%
3Y Rtn-88.5%92.1%1.2%140.6%-25.1%337.0%46.7%
1M Excs Rtn-32.2%5.4%-4.5%16.8%3.5%-2.4%0.6%
3M Excs Rtn-28.4%1.4%-13.2%10.3%-6.4%6.1%-2.5%
6M Excs Rtn-37.6%22.3%-12.3%29.5%0.5%-11.5%-5.5%
12M Excs Rtn-62.1%26.9%-26.0%51.1%-19.7%6.4%-6.6%
3Y Excs Rtn-159.7%29.1%-61.4%81.6%-87.3%277.9%-16.2%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Fire safety equipment10   
Safety aparel00   
Project - supply & installation00   
Maintenance & Servicing00   
Clinical trial supply00   
Development of innovative cancer medicines based on cell cycle, transcriptional regulation and  000
Total10000


Operating Income by Segment
$ Mil20242023
Development of innovative cancer medicines based on cell cycle, transcriptional regulation and-12-25
Total-12-25


Net Income by Segment
$ Mil20242023
Development of innovative cancer medicines based on cell cycle, transcriptional regulation and-11-23
Total-11-23


Assets by Segment
$ Mil20222021202020192017
Development of innovative cancer medicines based on cell cycle, transcriptional regulation and2843371526
Total2843371526


Price Behavior

Price Behavior
Market Price$0.57 
Market Cap ($ Bil)0.0 
First Trading Date05/05/2004 
Distance from 52W High-68.4% 
   50 Days200 Days
DMA Price$0.87$0.93
DMA Trenddowndown
Distance from DMA-34.1%-38.2%
 3M1YR
Volatility90.6%113.0%
Downside Capture42.98115.94
Upside Capture-106.7729.70
Correlation (S&P 500)-8.0%6.7%
BGMS Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta-1.12-0.700.25-0.481.04-0.35
Up Beta0.190.722.603.823.34-0.39
Down Beta-2.50-1.90-2.22-5.72-1.170.72
Up Capture-26%-31%36%2%43%-1%
Bmk +ve Days12182862130427
Stock +ve Days9172853105117
Down Capture-55%-67%36%30%133%92%
Bmk -ve Days10253664121325
Stock -ve Days13263671137158

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with BGMS
BGMS-52.6%113.0%-0.16-
Sector ETF (XLI)10.7%18.3%0.403.6%
Equity (SPY)10.9%13.8%0.498.0%
Gold (GLD)-8.2%29.0%-0.302.0%
Commodities (DBC)28.8%21.5%1.07-4.0%
Real Estate (VNQ)11.2%14.2%0.505.6%
Bitcoin (BTCUSD)-29.6%43.7%-0.6919.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with BGMS
BGMS-35.7%117.7%-1.05-
Sector ETF (XLI)10.8%17.8%0.445.8%
Equity (SPY)11.0%17.3%0.4610.1%
Gold (GLD)14.5%19.2%0.60-0.1%
Commodities (DBC)6.8%19.6%0.24-4.1%
Real Estate (VNQ)1.1%19.0%-0.055.5%
Bitcoin (BTCUSD)-0.0%51.4%0.1817.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with BGMS
BGMS-19.8%117.7%-1.05-
Sector ETF (XLI)12.9%20.1%0.565.8%
Equity (SPY)14.9%18.0%0.7010.1%
Gold (GLD)10.9%16.6%0.53-0.1%
Commodities (DBC)7.2%18.2%0.31-4.1%
Real Estate (VNQ)5.8%20.7%0.245.5%
Bitcoin (BTCUSD)57.1%66.3%0.9717.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity0.0 Mil
Short Interest: % Change Since 10152026-10.2%
Average Daily Volume0.0 Mil
Days-to-Cover Short Interest1.2 days
Basic Shares Quantity6.6 Mil
Short % of Basic Shares0.4%

Earnings Returns History

Updated 11/17/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/2026-9.8%  
8/14/2026-1.1%-5.4%-3.0%
5/14/2026-5.1%-6.1%-20.5%
11/13/2025-2.2%-8.2%0.0%
SUMMARY STATS   
# Positive001
# Negative432
Median Positive  0.0%
Median Negative-3.7%-6.1%-11.7%
Max Positive  0.0%
Max Negative-9.8%-8.2%-20.5%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/2026-9.8%  
8/14/2026-1.1%-5.4%-3.0%
5/14/2026-5.1%-6.1%-20.5%
11/13/2025-2.2%-8.2%0.0%
SUMMARY STATS   
# Positive001
# Negative432
Median Positive  0.0%
Median Negative-3.7%-6.1%-11.7%
Max Positive  0.0%
Max Negative-9.8%-8.2%-20.5%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/12/202610-Q
06/30/202608/14/202610-Q
03/31/202605/15/202610-Q
12/31/202503/30/202610-K
09/30/202511/13/202510-Q
06/30/202508/14/202510-Q
03/31/202505/14/202510-Q
12/31/202404/02/202510-K
09/30/202411/12/202410-Q
06/30/202408/14/202410-Q
03/31/202405/14/202410-Q
12/31/202303/21/202410-K
09/30/202311/29/202310-Q
06/30/202308/10/202310-Q
03/31/202305/11/202310-Q
12/31/202203/08/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/12/202610-Q
06/30/202608/14/202610-Q
03/31/202605/15/202610-Q
12/31/202503/30/202610-K
09/30/202511/13/202510-Q
06/30/202508/14/202510-Q
03/31/202505/14/202510-Q
12/31/202404/02/202510-K
09/30/202411/12/202410-Q
06/30/202408/14/202410-Q
03/31/202405/14/202410-Q
12/31/202303/21/202410-K
09/30/202311/29/202310-Q
06/30/202308/10/202310-Q
03/31/202305/11/202310-Q
12/31/202203/08/202310-K
09/30/202211/10/202210-Q
06/30/202208/11/202210-Q
03/31/202205/12/202210-Q
12/31/202103/30/202210-K
09/30/202111/12/202110-Q
06/30/202108/12/202110-Q
03/31/202105/14/202110-Q
12/31/202003/01/202110-K
09/30/202011/12/202010-Q
06/30/202008/13/202010-Q
03/31/202005/12/202010-Q
12/31/201903/05/202010-K

Insider Activity

Updated 4/26/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Yap, Kim ChoyDirectSell110520251.7028,540  Form
2Yap, Kim ChoyDirectSell110320251.81112,260202,85451,500Form
3Kua, Khai LoonDirectSell110320251.80242,477  Form
4Ong, Yee LungDirectSell110320251.80248,814  Form
5Yap, Kim ChoyDirectSell103120251.83110,749203,114258,154Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Yap, Kim ChoyDirectSell110520251.7028,540  Form
2Yap, Kim ChoyDirectSell110320251.81112,260202,85451,500Form
3Kua, Khai LoonDirectSell110320251.80242,477  Form
4Ong, Yee LungDirectSell110320251.80248,814  Form
5Yap, Kim ChoyDirectSell103120251.83110,749203,114258,154Form
6Yap, Kim ChoyDirectSell103020251.8313,11123,967459,758Form
7Yap, Kim ChoyDirectSell102920252.12120,250254,690560,465Form
8Ong, Yee LungDirectSell102820251.9919,85839,517495,140Form
9Yap, Kim ChoyDirectSell102820251.9019,59537,270732,023Form
10Fitters, Diversified BerhadDirectSell102320253.0092,352277,518839,140Form
11Fitters, Diversified BerhadDirectSell102220253.09108,107333,8341,147,501Form
12Kua, Khai LoonDirectSell102020254.2288,204371,9561,022,526Form
13Fitters, Diversified BerhadDirectSell102020255.5026,051143,2802,638,388Form
14Kua, Khai LoonDirectSell102020255.667,47942,3391,871,985Form
15Ong, Yee LungDirectSell101620256.00135,793814,7581,612,032Form
16Fitters, Diversified BerhadDirectSell101420255.2651,400270,2612,659,276Form
17Fitters, Diversified BerhadDirectSell101020255.29142,000751,6062,949,037Form
18Kua, Khai LoonDirectSell101020255.1325,000128,3001,735,437Form
19Kua, Khai LoonDirectSell101020256.2222,251138,4902,260,308Form
20Kua, Khai LoonDirectSell91020257.0119,054133,5692,701,731Form
21Lazar, David EDirectSell804202512.366,75083,4301,926,158Form
Core Cache Last Updated: 11/18/2026